US3257276A - Oral analgesic preparation - Google Patents

Oral analgesic preparation Download PDF

Info

Publication number
US3257276A
US3257276A US190235A US19023562A US3257276A US 3257276 A US3257276 A US 3257276A US 190235 A US190235 A US 190235A US 19023562 A US19023562 A US 19023562A US 3257276 A US3257276 A US 3257276A
Authority
US
United States
Prior art keywords
salicylate
preparation
gel
pain
gum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US190235A
Inventor
Robert H Broh-Kahn
Ernest J Sasmor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAB FOR PHARMACEUTICAL DEV Inc
LABORATORIES FOR PHARMACEUTICAL DEVELOPMENT Inc
Original Assignee
LAB FOR PHARMACEUTICAL DEV Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NL287272D priority Critical patent/NL287272A/xx
Priority to NL31756D priority patent/NL31756C/xx
Priority to BE626627D priority patent/BE626627A/xx
Application filed by LAB FOR PHARMACEUTICAL DEV Inc filed Critical LAB FOR PHARMACEUTICAL DEV Inc
Priority to US190235A priority patent/US3257276A/en
Priority to GB49070/62A priority patent/GB979909A/en
Application granted granted Critical
Publication of US3257276A publication Critical patent/US3257276A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01CRESISTORS
    • H01C3/00Non-adjustable metal resistors made of wire or ribbon, e.g. coiled, woven or formed as grids
    • H01C3/04Iron-filament ballast resistors; Other resistors having variable temperature coefficient

Definitions

  • This invention relates to an improved medicinal composition adapted for use on the gingival and lip surfaces as well as on the mucosa of the buccal and oral cavity in general, said surfaces and mucosa being referred to herein as the oral mucosa, in order to achieve relief of pain.
  • Deciduous teeth are twenty in number and first appear at six to eight months of age. up to approximately 30 months of age and it appears that many infants are in need of some comfort of irritating symptomatology resulting from this physiologic process for approximately the first two and one-half years of their life.
  • Painful conditions peculiar to the gingivae and mucosal membranes in and about the oral cavity are well known. Relief of pain associated with these conditions has been an especially diflicult problem.
  • the commonly practiced dental, surgical procedure of multiple extraction of diseased teeth has'created problems of effective pain control during the post-operative period.
  • a wide area of gingival tissue becomes painful and generally exhibits a local inflammatory response to the surgical trauma.
  • the practice of suturing the wound in order to prevent excessive bleeding gives rise to prolonged pain during the postoperative period.
  • This practice is further complicated by other advances in dental science which now permit the immediate insertion of new dentures after surgery. It is an extremely difficult process to achieve pain relief in these conditions.
  • Local anesthetic agents are generally not utilized because of their transient period of activity as well as the great danger of allergic reactions arising from their multiple use.
  • Relief of pain may be achieved through four fundamental methods. These are: (a) removing the underlying cause of the pain; (b) blocking the pathway of the painful impulses; (c) raising the pain threshold; or (d) suppressing the pain reaction by depressing the cortical area of the brain.
  • the removal of the cause of the pain is the most desirable method of pain relief, but this is not always possible.
  • pain, after surgery arises from the trauma to the tissues and will disappear when this injury has been resolved. During the period of healing, however, pain will be present as a natural consequence to surgery. On the other hand, in certain infectious states, the pain may be relieved to a very great degree 'and about the buccal cavity.
  • the raising of the pain threshold will generally involve a central nervous system effect, this may also be achieved by modifying or altering the response at the peripheral or cellular level.
  • topical local anesthetic renders the area insensitive to pain by blocking the perception of these painful stimuli. While this may be considered to be a special form of nerve blockade, it is generally recognized that the essential physiology of nerve transmission remains intact although the response of the nerve endings in their sensitivity to painful stimuli, has been altered.
  • a particular advantage of the use of the product of this invention is that it will provide effective pain relief to these common and distressing painful symptoms without subjecting the patient to the noxious effects of large quantities of systemically 'acting analgesic agents, nor does this product influence the functioning of the cardiovascular system, the renal system and central nervous system as would be observed after the use of narcotic, sedative and tranqualizing medications.
  • This new material may be used for infants. No allergic side reactions have been reported.
  • Any water soluble salicylate as for example, choline salicylate, potassium salicylate, sodium salicylate, calcium salicylate and morpholine salicylate may be used to achieve this effect.
  • choline salicylate is a preferred compound.
  • an optimal concentration will be approximately 7.5 percent with an effective range of from 2 to. 10 percent.
  • the preferred pH for the preparation containing choline salicylate is between pH 5.5 and pH 6.5, although a pH range of 4 to 7 may be employed.
  • the preferred dosage form is a hydroalcoholic gel although an aqueous gel may be used.
  • aqueous gel or hydroalcoholic gel to be used as a vehicle for the salicylate ion
  • gelling agents as methyl cellulose, methylethyl cellulose, polyoxyethylene glycol, polyvinyl pyrrolidone, dextran, gum guar, algin gum, gum acacia and gum tragacanth.
  • a preferred gelling agent is methyl cellulose.
  • Methocel-4000 a proprietary form of methyl cellulose, has been found particularly useful. This form has a viscosity of 4000 centipoises when a 2 percent aqueous solution is maintained at 20 C.
  • concentration of the gelling agent ranges from 0.1 to 4 percent, depending upon the desired viscosity of the finished gel as well as the physical properties of the particular gelling agent selected.
  • the gel is prepared by dispersing the gelling compound in the selected menstrum which may be water or hydroalcoholic solutions containing from to 60 percent of alcohol, containing the appropriate quantity of the selected water soluble salicylate and the pH adjusted, if necessary, to the desired range.
  • the finished gel may be flavored with appropriate aromatic substances.
  • An antiseptic may be incorporated into the gel and compounds such as .cetyldimethylbenzylammonium chloride, in concentrations of from 0.005 to 0.05 percent; penicillin and penicillin salts, from 100,000 to 1 million units per gram; tyrothrycin from 2 to 5 mg. per gram; tetracyline, from 5 to mg. per gram and neomycin, 5 mg. per gram, may be utilized.
  • compounds such as .cetyldimethylbenzylammonium chloride, in concentrations of from 0.005 to 0.05 percent; penicillin and penicillin salts, from 100,000 to 1 million units per gram; tyrothrycin from 2 to 5 mg. per gram; tetracyline, from 5 to mg. per gram and neomycin, 5 mg. per gram, may be utilized.
  • the alcoholic solution is then mixed with the aqueous solution while stirring and the whole gently warmed to about 50 C. and filtered.
  • the solution is brought to proper volume with additional quantities of water. On cooling, a clear viscous gel forms which is suitable for application to the painful area.
  • the aqueous dispersion of the gelling agent is added slowly, with constant stirring, to the warmed (to 4050 C.) alcohol solution prepared earlier.
  • the mixture is filtered and the pH of the solution determined.
  • the pH is then adjusted to ph 6 with choline base, or with salicylic acid, depending on whether the original pH of the mixture is greater or lesser than pH 6.
  • the dispersion is then brought to proper volume, gm., with distilled water, and allowed to cool. On cooling the mixture forms a semisolid g'el, suitable for application to the oral mucosa.
  • the antiseptic may be omitted.
  • Example 2 In place of the choline salicylate used there may be substituted any water soluble salicylate, as for example, sodium salicylate, potassium salicylate, calcium salicylate and morpholine salicylate, in a concentration of from 2 to 10 percent by weight of salicylate ion of the quantity of gel prepared. If necessary, the pH of the gel should then be adjusted to approximately pH 5-7 by the addition of the required amount of non-toxic acid or base.
  • any water soluble salicylate as for example, sodium salicylate, potassium salicylate, calcium salicylate and morpholine salicylate, in a concentration of from 2 to 10 percent by weight of salicylate ion of the quantity of gel prepared. If necessary, the pH of the gel should then be adjusted to approximately pH 5-7 by the addition of the required amount of non-toxic acid or base.
  • Example 3 In place of cetyldimethylbenzylammonium chloride used in Example 1 there may be substituted, in respective amounts, such germicidal substances as: penicillin and penicillin salts in concentration of from 100,000 to 1 million units per gram of preparation; tyrothricin, from 2 to 5 mgm. per gram of preparation; tetracycline, from 5 to 15 mg. per gram of preparation; and neomycin, 5 mg.
  • germicidal substances as: penicillin and penicillin salts in concentration of from 100,000 to 1 million units per gram of preparation; tyrothricin, from 2 to 5 mgm. per gram of preparation; tetracycline, from 5 to 15 mg. per gram of preparation; and neomycin, 5 mg.
  • Example 2 When it is desired to obtain relief of pain arising from the gingival mucosa or the oral mucosa, a small amount of gel containing the water soluble salicylate is applied to the affected area, from one to six times daily, depending upon the severity of the pain. Gentle massage is used to assure penetration, and an even distribution. A prompt relief of pain results after application.
  • a small amount of the gel In applying the gel to relieve the pain resulting from new dentures, a small amount of the gel. is applied directly to the gingival surface and an additional quantity may be distributed over the surface of the denture, coming in contact with the gingival tissue.
  • the applications may be repeated as often as is necessary although from 1 to 6 times daily is the preferred regimen.
  • a small amount of the gel is applied directly to the affected area. Pain relief will be prompt without a numbing sensation and the applications of the agent may be repeated from 1 to 4 times daily.
  • An analgesic preparation for the application to the oral mucosa comprising a gel selected from the group consisting of aqueous and hydroalcoholic gels and a water soluble salicylate compound dissolved in said gel, said preparation having a pH of from pH 4 through pH 7 and the salicylate ion content of said compound being from 2 percent to percent by weight of said preparation.
  • An analgesic preparation for application to the oral mucosa comprising a gel selected from the group consisting of aqueous and hydroalcoholic gels and choline salicylate dissolved in said gel, the salicylate ion content of said choline Salicylate being from 2 percent to 10' percent by weight of said preparation and the pH of said preparation being from pH 4 through pH 7.
  • An analgesic preparation for application to the oral mucosa comprising a gel selected from the group consisting of aqueous and hydroalcoholic gels and morpholine. salicylate dissolved in said gel, the salicylate ion con, tent of said morpholine salicylate being from 2 percent to 10 percent by weight of said preparation and the pH of said preparation being from pH 4 through pH 7.
  • An analgesic preparation for application to the oral mucosa comprising a gel selected from the group consisting of aqueous and hydroalcoholic gels and sodium sa- 8 licylate dissolved in-said gel, the salicylateion content of. said sodium salicylate being from 2 to 10' percent by weight of said preparation and the pH of said preparation being from pH 4 through pH 7.
  • FRANK CACCIAPAGLIA, JR;, EUGENE FRANK,

Abstract

An analgesic preparation for application to the oral mucosa (including the gingival and lip surfaces) comprises an aqueous or hydroalcoholic gel and a water-soluble salicylate compound dissolved in said gel, said preparation having a pH of from 4 to 7. Generally, the preparation has a salicylate ion concentration of 2 to 10% by weight. Salicylate compounds specified are choline, potassium, sodium, calcium and morpholine salicylates. The gelling agent for the preparation may be methyl cellulose, methyl ethyl cellulose, polyoxythylene glycol, polyvinyl pyrrolidone, dextran, gum guar, algin gum, gum acacia or gum tragacanth. Optional ingredients include antiseptics, e.g. cetyldimethylbenzylammonium chloride, antibiotics, e.g. penicillin and penicillin salts, tyrothricin, tetracycline and neomycin, and flavouring and sweetening agents, e.g. cyclohexylsulphamic acid.

Description

, compound.
United States Patent 3,257,276 ORAL ANALGESHC PREPARATION Robert H. Broh-Kahn, Hastings on Hudson, and Ernest J. Sasmor, Yonkers, N.Y., assignors to Laboratories for Pharmaceutical Development, Inc., a corporation of New York No Drawing. Filed Apr. 26, 1962, Ser. No. 190,235 8 Claims. (Cl. 167-65) This invention relates to an improved medicinal composition adapted for use on the gingival and lip surfaces as well as on the mucosa of the buccal and oral cavity in general, said surfaces and mucosa being referred to herein as the oral mucosa, in order to achieve relief of pain. In particular, it-is concerned with the use of organic or inorganic water soluble salicylates, as for example, choline salicylate, sodium salicylate, potassium salicylate, calcium salicylate and m-orpholine salicylate, dissolved in a special vehicle which modifies the penetration of the active moiety in order to permit the attainment of therapeutically significant blood levels and, at the same time, to permit high local concentrations of the active theabsorption of the active moiety as well as the attainment of high local concentrations, that affords maximal pain relief with minimal amounts of the water soluble salicylate used. Thus, through this double action, the effective concentration of the therapeutically active substance of this new product is materially less than would be required to produce an equal pharmacologic effect through a systemic action.
Eruption of deciduous teeth in infants is often associated with much pain and suffering. The gingivae at the point of emergence of the new deciduous teeth, may become swollen, inflamed and sensitive to contact and pressure, thereby producing irritability, fretfulness, disturbed sleep and excessive salivation. On occasion, an eruptive gingivitis during teething may become complicated by the development of a hemorrhagic cyst which is visible in the area overlying the emerging tooth. The infants response depends largely upon the severity of the pain. In an article appearing in the Journal of Dentistry of Children (volume 19, page 127-132, 1952), it was reported that, the emotionality of the baby between the ages of six months and 30 months may be traced by the cutting of teeth. Each new tooth is accompanied by some physical upset, even though it may be of a minor sort, and this predisposes the baby to general irritability.
Deciduous teeth are twenty in number and first appear at six to eight months of age. up to approximately 30 months of age and it appears that many infants are in need of some comfort of irritating symptomatology resulting from this physiologic process for approximately the first two and one-half years of their life.
Lancing the gingivae over the bulging, emerging tooth was a common practice for manycenturies. During the 19th century, the practice of providing soothing powders and syrups containing various preparations of opium, such as tincture of opium, became common. In more recent years the use of sedatives, hypnotics and other analgesic substances have been suggested. These are generally frowned upon because of the high order of toxicity and addiction resulting from the injudicious use of these potent substances.
Present therapy appears to depend largely upon the severity of the accompanying symptomatology. Small doses of sedatives and antipyretics under physician control, have been utilized. Local massage with aromatic compounds as well as the application to the gingival surface of small doses of alcohol has also been suggested. Where the discomfort and irritability are more pro- The teething process lasts It is by virtue of this special property of 3,257,275 Patented June 21, 1966 ice nounced, chloral hydrate, a powerful hypnotic, has been utilized. The use of the more potent local anesthetic compounds have been deplored because of their pronounced tendency to cause allergic reactions.
Painful conditions peculiar to the gingivae and mucosal membranes in and about the oral cavity are well known. Relief of pain associated with these conditions has been an especially diflicult problem. Thus, the commonly practiced dental, surgical procedure of multiple extraction of diseased teeth has'created problems of effective pain control during the post-operative period. A wide area of gingival tissue becomes painful and generally exhibits a local inflammatory response to the surgical trauma. When a large number of teeth are extracted at one time, the practice of suturing the wound in order to prevent excessive bleeding, gives rise to prolonged pain during the postoperative period. This practice is further complicated by other advances in dental science which now permit the immediate insertion of new dentures after surgery. It is an extremely difficult process to achieve pain relief in these conditions. Local anesthetic agents are generally not utilized because of their transient period of activity as well as the great danger of allergic reactions arising from their multiple use.
The modern use of artificial dentures to replace missing or extracted teeth is another cause of painful conditions of the mouth. A new dental technique permits the denture to be inserted into the patients mouth as soon as the teeth have been extracted, and this technique is known as immediate denture method. Under this practice, the gums are sutured after extraction of the teeth in order to lessen the healing time required as well as to prevent excessive blood loss and the previously prepared denture is immediately inserted. It is the usual practice to permit this denture to remain in the mouth substantially continuously during the first seventy-two hour period subsequent to extraction in order to minimize the excessive swelling of the gingival tissue and to insure that healing will take place in the same contour as had previously existed. Maintaining these artificial dentures during the first seventy-two hours is often a painful experience.
A similar problem exists with the older procedure of utilizing dentures to replace missing teeth. These are inserted four to six weeks after the extraction of teeth, subsequent to substantial healing of the alveolar ridges of the gums. These new dentures often result in pain to the patient during the initial period of adaptation since it is virtually impossible to prepare a prosthetic appliance which corresponds exactly to the contour and shape of the gingival surface.
Still another painful condition arises in the oral cavity which involves the oral mucosal membrances and these are thoselocal infiammations and abraded areas as a result from ecrtain infections, as for example, the common cold sore, the fever-blister or herpes simplex, which arises predominantly on the lips. Included among these painful conditions are mechanical irritations resulting from accidental biting of the internal membranes of the mouth and also local infections of the mucosal surface, per se.
Relief of pain may be achieved through four fundamental methods. These are: (a) removing the underlying cause of the pain; (b) blocking the pathway of the painful impulses; (c) raising the pain threshold; or (d) suppressing the pain reaction by depressing the cortical area of the brain. The removal of the cause of the pain is the most desirable method of pain relief, but this is not always possible. Thus, pain, after surgery, arises from the trauma to the tissues and will disappear when this injury has been resolved. During the period of healing, however, pain will be present as a natural consequence to surgery. On the other hand, in certain infectious states, the pain may be relieved to a very great degree 'and about the buccal cavity. The use of local anesthetics which are injected into the tissue about the nerve is the accepted and most common anesthetic procedure for dental surgery pain control. Although local anesthetics are used almost exclusively for the operative period and I have, on occasion, been used for acute painful states because of their short period of pain relief, these agents do not lend themselves to continuous or multiple and repeated applications.
The use of large amounts of systemic analgesics to depress the pain reaction has as its principal drawback, the fact that a general systemic effect is achieved when only a local action is desired. Thus, it is unwise to dull the perception of the patient as well as to subject the cardiovascular, renal and pulmonary systems to the depressant effects of an analgesic, sedative or hypnotic agent when effective pain control may be achieved by local application.
Although the raising of the pain threshold will generally involve a central nervous system effect, this may also be achieved by modifying or altering the response at the peripheral or cellular level. Thus, the application of topical local anesthetic renders the area insensitive to pain by blocking the perception of these painful stimuli. While this may be considered to be a special form of nerve blockade, it is generally recognized that the essential physiology of nerve transmission remains intact although the response of the nerve endings in their sensitivity to painful stimuli, has been altered.
It is, therefore, evident that pain arising from the mucosal and gingival tissue in and about the oralor buccal cavity may result from a multiplicity of causes. Nevertheless, the approach to the management of these' painful states is the same despite the variety of causes. We have found that the application of the product of the present invention to the surface of the buccal mucosa and gingival tissue in and about the .mouth, will result in a prompt relief of these painful states without disagreeable or unwanted side reactions. A particular advantage of the use of the product of this invention is that it will provide effective pain relief to these common and distressing painful symptoms without subjecting the patient to the noxious effects of large quantities of systemically 'acting analgesic agents, nor does this product influence the functioning of the cardiovascular system, the renal system and central nervous system as would be observed after the use of narcotic, sedative and tranqualizing medications. This new material may be used for infants. No allergic side reactions have been reported.
We have found that the application of a water soluble salicylate in an aqueous alcoholic and hydroalcoholic gel, wherein the concentration of the salicylate ion is from 2 to 10 percent and the whole buffered to a range of from pH 4 to pH 7; will cause prompt, effective relief of pain. Unexpectedly, this result occurs despite the fact that the concentration of salicylate ions is far below that required to exert an effect or to produce significant elevations in the blood level of salicylate ions when the active compound is administered either orally or rectally. This high degree of pain relief is achieved because of the particular action of this form of salicylate ions in the specially buffered media, which permits the attainment of maximal local cellular concentrations of the salicylate ion while, at the same time, permitting absorption in order to obtain benefit of systemic analgesia.
These unique actions of the invention we describe sharply distinguish it from the water insoluble salicylates such as aspirin and salicylic acid that have frequently been used in attempts to obtain relief from painful conditions in the mouth through their local application. Thus, the authoritative Second Edition of Pharmacology in Medicine edited by Victor Drill, Ph.D., M.D., at page 293 states, Careful studies in man have shown that when aspirin is placed in the mouth absorption is negligible if the patients are warned not to swallow their saliva.
Since it is obviously very difficult to make certain that a patient does not swallow his saliva and thus enable a salicylate originally present in his oral cavity to be absorbed via the stomach, the unique property of our invention was demonstrated as follows: Five ml. of a hydroalcoholic gel containing 436 mg. choline salicylate were placed in the buccal cavity of each of two anesthetized rabbits in whom the esophagus had previously been ligated to prevent accidental swallowing of the preparation and in whom a tracheal cannula was inserted both to provide proper ventilation and to insure that none of the preparation could be aspirated into the bronchial tract from which it might be absorbed. Blood samples were withdrawn at 5, 15, 30, and 120 minutes and the plasma salicylate levels determined by conventional technics. The results,
as indicated in Table I, demonstrate rapid absorption of salicylate from the mouth, as present in this preparation.
TABLE I.PLASMA SALICYLATE LEVELS IN RABBITS PREPARED AS DESCRIBED IN THE TEXT macological Basis of Therapeutics by Louis Goodman, M.D., and Alfred Gilman, Ph.D., at page 284 states, The use of aspirin locally for alleviating dental pain or sore throat has no rational basis. As will be demonstrated, the use of the type of hydroalcoholic gel described above in actual clinical trials does provide effective relief from such pain.
Any water soluble salicylate, as for example, choline salicylate, potassium salicylate, sodium salicylate, calcium salicylate and morpholine salicylate may be used to achieve this effect. In practice, it has been found that choline salicylate is a preferred compound. When choline salicylate is used to achieve the pain relief in and about the oral cavity, an optimal concentration will be approximately 7.5 percent with an effective range of from 2 to. 10 percent. The preferred pH for the preparation containing choline salicylate is between pH 5.5 and pH 6.5, although a pH range of 4 to 7 may be employed. The preferred dosage form is a hydroalcoholic gel although an aqueous gel may be used.
In preparing an aqueous gel or hydroalcoholic gel to be used as a vehicle for the salicylate ion, there may be employed such gelling agents as methyl cellulose, methylethyl cellulose, polyoxyethylene glycol, polyvinyl pyrrolidone, dextran, gum guar, algin gum, gum acacia and gum tragacanth. A preferred gelling agent is methyl cellulose. The preparation known as Methocel-4000, a proprietary form of methyl cellulose, has been found particularly useful. This form has a viscosity of 4000 centipoises when a 2 percent aqueous solution is maintained at 20 C. The concentration of the gelling agent ranges from 0.1 to 4 percent, depending upon the desired viscosity of the finished gel as well as the physical properties of the particular gelling agent selected.
The gel is prepared by dispersing the gelling compound in the selected menstrum which may be water or hydroalcoholic solutions containing from to 60 percent of alcohol, containing the appropriate quantity of the selected water soluble salicylate and the pH adjusted, if necessary, to the desired range. The finished gel may be flavored with appropriate aromatic substances.
An antiseptic may be incorporated into the gel and compounds such as .cetyldimethylbenzylammonium chloride, in concentrations of from 0.005 to 0.05 percent; penicillin and penicillin salts, from 100,000 to 1 million units per gram; tyrothrycin from 2 to 5 mg. per gram; tetracyline, from 5 to mg. per gram and neomycin, 5 mg. per gram, may be utilized.
A preferred effective formulation of the choline salicylate gel preparation is as follows:
Grams Choline salicylate 8.72 Cetyldimethylbenzylammonium chloride 0.01- Methylcellulose4,'000 2.75 Glycerine 5 Ethyl alcohol 39.16 Oil of anise 0.143 Menthol 0.057 Cyclohexylsulfamic acid 0.2 Waterq.s.d 100 The glycerine is combined with the alcohol and the cyclohexylsulfamic acid, menthol and oil anise is dissolved in this solution. The cetyldimethylbenzylammonium chloride is dissolved in approximately three-fourths the required volume of water and when solution has been achieved, the methylcellulose is dispersed in the aqueous solution and the choline salicylate added. The alcoholic solution is then mixed with the aqueous solution while stirring and the whole gently warmed to about 50 C. and filtered. The solution is brought to proper volume with additional quantities of water. On cooling, a clear viscous gel forms which is suitable for application to the painful area.
A number of clinical studies evaluating the degree of pain relief afforded by the application of the product of the present invention to the mucosa of the oral cavity in more than 350 infant patients, established the desirable beneficial properties of this new preparation. All of the patients evidenced painful and distressing disturbances which accompanied the teething process. The most common symptoms reported were crying, irritability, restlessness, fever, refusal to eat, sleeplessness at night, drooling and thumb-sucking. Some of the patients presented the more severe symptoms of anorexia,-vomiting and diarrhea.
After application of the choline salicylate gel to the gingival surface, prompt effective pain relief was observed and results of the study of 387 patients were classified as good to excellent in 339 infants or 87.6 percent of the group studied. The results were fair for 12 patients and there was a poor response observed in 36 patients (9.3%).
The acceptance of the preparation by the patient was unanimously favorable and this included a group of 11 infants in whom the gel remained in contact with the gingival surface for an extended period of time.
In another study the effect of the choline salicylate gel. for the relief of pain associated with dentition in infants, evaluatedby a double-blind technique, in which a group of 28 infants of from 4 to 15 months of age were treated with the active teething-gel of the present invention, and a control group of 21 infants of a similar age distribution were treated with a placebo or inactive gel preparation. All of the infants showed objective signs of distress such as fretfulness, drooling and crying before the study was started and about one-third of the group refused food, while two-thirds of the group had gingival hyperemia, two-thirds, a gingival edema and of this latter group, one-third showed findings of both.
-A small portion of a coded test preparation was carefully massaged onto the infants gums and this was repeated three to four times daily as long as there were recurring signs of distress. The mothers were instructed to time the latent period between successive applications and apparent relief onset. The results of the study indicated that the active test preparation was effective to an excellent degree in 23 patients or 82 percent, and to a good degree in 9 patients or 18 percent. There were no failures in this test group. In contrast to this finding, the placebo medication afforded the following results: 7 patients, excellent; 7 patients, good and 7 patients, poor.,
There were no side reactions observed in any of the patients of either group.
The latent period between the application of the active' To prepare the analgesic gel, choline salicylate, 8.72 gm. and cetyldimethylbenzylammonium chloride, 0.01 gm. are added to 39.16 gm. of ethyl alcohol. To this solution is added 0.143 gm. of oil of anise, 0.057 gm. of menthol and 0.2 gm. of cyclohexysulfamic acid. The mixture is stirred until complete solution is achieved. In a separate flask containing 40 ml. of distilled water, is dispersed 2.75 gm. of methyl cellulose-4000, and the dis persion heated to 50 C. To this mixture is added 5 gm. of glycerin. The aqueous dispersion of the gelling agent is added slowly, with constant stirring, to the warmed (to 4050 C.) alcohol solution prepared earlier. The mixture is filtered and the pH of the solution determined. The pH is then adjusted to ph 6 with choline base, or with salicylic acid, depending on whether the original pH of the mixture is greater or lesser than pH 6. The dispersion is then brought to proper volume, gm., with distilled water, and allowed to cool. On cooling the mixture forms a semisolid g'el, suitable for application to the oral mucosa. Of course, if mere pain relief is sought, the antiseptic may be omitted.
Example 2 In place of the choline salicylate used there may be substituted any water soluble salicylate, as for example, sodium salicylate, potassium salicylate, calcium salicylate and morpholine salicylate, in a concentration of from 2 to 10 percent by weight of salicylate ion of the quantity of gel prepared. If necessary, the pH of the gel should then be adjusted to approximately pH 5-7 by the addition of the required amount of non-toxic acid or base.
Example 3 Example 4 In place of cetyldimethylbenzylammonium chloride used in Example 1 there may be substituted, in respective amounts, such germicidal substances as: penicillin and penicillin salts in concentration of from 100,000 to 1 million units per gram of preparation; tyrothricin, from 2 to 5 mgm. per gram of preparation; tetracycline, from 5 to 15 mg. per gram of preparation; and neomycin, 5 mg.
per gram of preparation. These antibiotic substances are added after the solution has been filtered, but prior to the adjusting to final volume. The remainder of the steps being the same.
. Example When it is desired to obtain relief of pain arising from the gingival mucosa or the oral mucosa, a small amount of gel containing the water soluble salicylate is applied to the affected area, from one to six times daily, depending upon the severity of the pain. Gentle massage is used to assure penetration, and an even distribution. A prompt relief of pain results after application. In applying the gel to relieve the pain resulting from new dentures, a small amount of the gel. is applied directly to the gingival surface and an additional quantity may be distributed over the surface of the denture, coming in contact with the gingival tissue. The applications may be repeated as often as is necessary although from 1 to 6 times daily is the preferred regimen. When it is desired to treat the common cold sore or fever blister a small amount of the gel is applied directly to the affected area. Pain relief will be prompt without a numbing sensation and the applications of the agent may be repeated from 1 to 4 times daily.
What is claimed is:
1. An analgesic preparation for the application to the oral mucosa, comprising a gel selected from the group consisting of aqueous and hydroalcoholic gels and a water soluble salicylate compound dissolved in said gel, said preparation having a pH of from pH 4 through pH 7 and the salicylate ion content of said compound being from 2 percent to percent by weight of said preparation.
2. An analgesic preparation for application to the oral mucosa, comprising a gel selected from the group consisting of aqueous and hydroalcoholic gels and choline salicylate dissolved in said gel, the salicylate ion content of said choline Salicylate being from 2 percent to 10' percent by weight of said preparation and the pH of said preparation being from pH 4 through pH 7.
3. An analgesic preparation for application to the oral mucosa comprising a gel selected from the group consisting of aqueous and hydroalcoholic gels and morpholine. salicylate dissolved in said gel, the salicylate ion con, tent of said morpholine salicylate being from 2 percent to 10 percent by weight of said preparation and the pH of said preparation being from pH 4 through pH 7.
4. An analgesic preparation for application to the oral mucosa comprising a gel selected from the group consisting of aqueous and hydroalcoholic gels and sodium sa- 8 licylate dissolved in-said gel, the salicylateion content of. said sodium salicylate being from 2 to 10' percent by weight of said preparation and the pH of said preparation being from pH 4 through pH 7.
5. The method of achieving oral mucosal analgesia which comprises applying to the oral mucosa of a human the preparation described in claim 1.
6. The method of achieving oral mucosal analgesia which comprises applying to the oral mucosa of .a human the preparation described in claim 2.
7. The method of achieving oral mucosal analgesia I which comprises applying to the oral mucosa of a human the preparation described in claim 3.
8. The method of achieving oral mucosal analgesia which comprises applying to the oral mucosa of a human the preparation described in claim 4.
References Cited by the Examiner FOREIGN PATENT 8/1957 Canada.
OTHER REFERENCES Davis, G. M., et al., A Preliminary Study on the Clinical Use of Choline Salicylate, in American Journal of the Medical Sciences, 239: pp. 47/273-51/277, March 1960.
Drill, V. A., Pharmacology in Medicine, New York, McGraw-Hill, 1954, Chapter 9, p. 9/5, column 1, lines 13-15, local anesthetic drugs.
Drug and Cosmetic Industry, p. 829, diethylamine salicylate, December 1955.
Gross, M., The Salicylates, New' Haven, Hillhouse Press, 1948, Chapter 5, pp. 149-150, therapeutic uses.
Modern Drug Encyclopedia, 8th Edition, 1961, p. 786, Myoflex cream. I
Modern Drug Encyclopedia, 8th Edition, 1961, p. 1410, Xylocaine jelly and Xylocaine viscous.
Reid, 1., Therapeutic Properties of Salicylate and Its Mode of Action, in Annals of the New York Acad. of Science, vol. 86, pp. 64-72, March 30, 1960.
Remingtons Practice of Pharmacy, 9th Edition, 1948, Chapter LXXV, p. 800, salicin, uses.
The Merck Index, 7th Edition, 1960, p. 902, retarcyl, 1960.
U.S.D., 24th Edition, 1947, p. 19, compound acetylsalicylic acid paste.
JULIAN S. LEVITT, Primary Examiner.
FRANK CACCIAPAGLIA, JR;, EUGENE FRANK,
MARTIN J. COHEN, Assistant Examiners.

Claims (1)

1. AN ANALGESIC PREPARTION FOR THE APPLICATION TO THE ORAL MUCOSA, COMPRISING A GEL SELECTED FROM THE GROUP CONSISTING OF AQUEOUS AND HYDROALCOHOLIC GELS AND A WATER SOLUBLE SALICYLATE COMPOUND DISSOLVED INSAID GEL, SAID PREPARATION HAVING A PH OF FROM PH4 THROUGH PH7 AND THE SALICYLATE ION CONTENT OF SAID COMPOUND BEING FROM 2 PERCENT TO 10 PERCENT BY WEIGHT OF SAID PREPARATION.
US190235A 1962-04-26 1962-04-26 Oral analgesic preparation Expired - Lifetime US3257276A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NL287272D NL287272A (en) 1962-04-26
NL31756D NL31756C (en) 1962-04-26
BE626627D BE626627A (en) 1962-04-26
US190235A US3257276A (en) 1962-04-26 1962-04-26 Oral analgesic preparation
GB49070/62A GB979909A (en) 1962-04-26 1962-12-31 Novel oral analgesic preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US190235A US3257276A (en) 1962-04-26 1962-04-26 Oral analgesic preparation

Publications (1)

Publication Number Publication Date
US3257276A true US3257276A (en) 1966-06-21

Family

ID=22700518

Family Applications (1)

Application Number Title Priority Date Filing Date
US190235A Expired - Lifetime US3257276A (en) 1962-04-26 1962-04-26 Oral analgesic preparation

Country Status (4)

Country Link
US (1) US3257276A (en)
BE (1) BE626627A (en)
GB (1) GB979909A (en)
NL (2) NL31756C (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0026332A2 (en) * 1979-10-01 1981-04-08 Richardson-Vicks, Inc. Non-adhesive gel composition for stabilizing dentures
US4590065A (en) * 1985-04-18 1986-05-20 Colgate-Palmolive Company Stable flavor-containing dentifrice
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US20040102429A1 (en) * 2002-02-07 2004-05-27 Modak Shanta M. Zinc salt compositions for the prevention of dermal and mucosal irritation
US20040219227A1 (en) * 2001-10-23 2004-11-04 Shanta Modak Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
US20050019431A1 (en) * 2003-07-17 2005-01-27 Modak Shanta M. Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
US20050048139A1 (en) * 2002-02-07 2005-03-03 Modak Shanta M. Zinc salt compositions for the prevention of dermal and mucosal irritation
US20070020342A1 (en) * 2002-02-07 2007-01-25 Modak Shanta M Non-irritating compositions containing zinc salts
US20090035390A1 (en) * 2006-01-06 2009-02-05 Modak Shanta M Compositions containing zinc salts for coating medical articles
US20090047357A1 (en) * 2005-12-22 2009-02-19 Otsuka Pharmaceutical Co., Ltd. Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
US20150335549A1 (en) * 2012-12-20 2015-11-26 Colgate-Palmolive Company Oral Care Composition Containing Ionic Liquids

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH655656B (en) * 1982-10-07 1986-05-15
DE3243546A1 (en) * 1982-11-25 1984-05-30 Bayer Ag, 5090 Leverkusen ANTIMYCOTIC AGENTS IN GEL FOR TREATING FUNGAL INFECTIONS OF THE ORAL CAVES
AU2252388A (en) * 1988-05-02 1989-11-29 Zila Pharmaceuticals Compositions and in situ methods for forming films on body tissue

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA545560A (en) * 1957-08-27 D. Waters Richard Analgesic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA545560A (en) * 1957-08-27 D. Waters Richard Analgesic composition

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0026332A2 (en) * 1979-10-01 1981-04-08 Richardson-Vicks, Inc. Non-adhesive gel composition for stabilizing dentures
EP0026332A3 (en) * 1979-10-01 1982-02-17 Richardson-Vicks, Inc. Non-adhesive gel composition for stabilizing dentures
DK155866B (en) * 1979-10-01 1989-05-29 Richardson Vicks Inc GEL-FREE GEL PREPARATION FOR STABILIZING DENTAL PROSTHESIS
US4590065A (en) * 1985-04-18 1986-05-20 Colgate-Palmolive Company Stable flavor-containing dentifrice
US5462749A (en) * 1991-09-25 1995-10-31 Mcnell-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5314915A (en) * 1991-09-25 1994-05-24 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6290984B1 (en) 1996-10-18 2001-09-18 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US20100305211A1 (en) * 2001-10-23 2010-12-02 Shanta Modak Gentle-Acting Skin-Disinfectants and Hydroalcoholic Gel Formulations
US8436050B2 (en) * 2001-10-23 2013-05-07 The Trustees Of Columbia University In The City Of New York Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
US20040219227A1 (en) * 2001-10-23 2004-11-04 Shanta Modak Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
US20040247685A1 (en) * 2001-10-23 2004-12-09 Shanta Modak Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
US8293802B2 (en) 2001-10-23 2012-10-23 The Trustees Of Columbia University Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
US7951840B2 (en) 2002-02-07 2011-05-31 Modak Shanta M Zinc salt compositions for the prevention of dermal and mucosal irritation
US20050048139A1 (en) * 2002-02-07 2005-03-03 Modak Shanta M. Zinc salt compositions for the prevention of dermal and mucosal irritation
USRE45435E1 (en) 2002-02-07 2015-03-24 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
US7745425B2 (en) 2002-02-07 2010-06-29 The Trustees Of Columbia University In The City Of New York Non-irritating compositions containing zinc salts
US20040102429A1 (en) * 2002-02-07 2004-05-27 Modak Shanta M. Zinc salt compositions for the prevention of dermal and mucosal irritation
US20070020342A1 (en) * 2002-02-07 2007-01-25 Modak Shanta M Non-irritating compositions containing zinc salts
US20110117140A1 (en) * 2002-02-07 2011-05-19 Modak Shanta M Zinc Salt Compositions for the Prevention of Dermal and Mucosal Irritation
US20110070316A1 (en) * 2003-07-17 2011-03-24 Modak Shanta M Antimicrobial Compositions Containing Synergistic Combinations of Quaternary Ammonium Compounds and Essential Oils and/or Constituents Thereof
US7871649B2 (en) 2003-07-17 2011-01-18 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
US20050019431A1 (en) * 2003-07-17 2005-01-27 Modak Shanta M. Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
US9421263B2 (en) 2003-07-17 2016-08-23 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
US20090047357A1 (en) * 2005-12-22 2009-02-19 Otsuka Pharmaceutical Co., Ltd. Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
US20090035390A1 (en) * 2006-01-06 2009-02-05 Modak Shanta M Compositions containing zinc salts for coating medical articles
US8207148B2 (en) 2006-01-06 2012-06-26 The Trustees Of Columbia University In The City Of New York Compositions containing zinc salts for coating medical articles
US7759327B2 (en) 2006-01-06 2010-07-20 The Trustees Of Columbia University In The City Of New York Compositions containing zinc salts for coating medical articles
US20150335549A1 (en) * 2012-12-20 2015-11-26 Colgate-Palmolive Company Oral Care Composition Containing Ionic Liquids
US9717667B2 (en) * 2012-12-20 2017-08-01 Colgate-Palmolive Company Oral care composition containing ionic liquids

Also Published As

Publication number Publication date
NL31756C (en)
NL287272A (en)
BE626627A (en)
GB979909A (en) 1965-01-06

Similar Documents

Publication Publication Date Title
US3257276A (en) Oral analgesic preparation
US4748022A (en) Topical composition
US3832460A (en) Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
DE69630460T2 (en) MEDICINAL PRODUCTS CONTAINING FLURBIPROP
US5977087A (en) Topical preparation for treatment of aphthous ulcers and other lesions
US20100247644A1 (en) Adhesive compositions for the treatment of xerostomia
US6159955A (en) Use of hyaluronic acid and a NSAID for the manufacture of a medicament for the treatment of mucosal diseases
US5541165A (en) Saliva substitute
US6103257A (en) System for delivering pharmaceuticals to the buccal mucosa
Dempster Post-tonsillectomy analgesia: the use of benzocaine lozenges
US4892877A (en) Antitussive liquid compositions containing phenol
US5331012A (en) Topical pharmaceutical preparation for fever blisters and other viral infections and method of use
Buglass Oral hygiene
EP0016183A1 (en) Medication for afflictions of the skin and mucosa
Quilligan et al. Double‐blind comparison of intravenously injected butorphanol and meperidine in parturients
JPH08295637A (en) Local administrative agent for oral cavity
JPS6259219A (en) Antitussive, expectorant, analgesic and sedative agent for external use
Hersh et al. A study of benzocaine gel dosing for toothache
Cade et al. Ketorolac or pethidine for analgesia after elective laparoscopic sterilization
Schaffer Clinical pathology of the tongue
Young A Comparative Study of Benzydamine Hydrochloride 0.15% wv (‘Diffiam’Pump Spray) and Placebo as Analgesics following Tonsillectomy
KR890007728A (en) Painkiller
Irwin et al. A comparative study of benzydamine hydrochloride 0· 15% w/v (‘Difflam’Oral Rinse) and acetyl salicylic acid as analgesics following tonsillectomy
JPH0466205B2 (en)
KANE JR Severe oral moniliasis complicating chlorpromazine therapy